MiNK Therapeutics (INKT) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

MiNK Therapeutics to Present INKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
MiNK TherapeuticsDec 18, 2024 00:00 ET
MiNK Therapeutics Is Maintained at Outperform by Baird
Dow JonesNov 15, 2024 07:31 ET · Ratings
MiNK Therapeutics Price Target Lowered to $4 From $8 at Baird
TipRanksNov 15, 2024 06:35 ET
MiNK Therapeutics Reports Q3 Growth and Strategic Advances
TipRanksNov 14, 2024 22:58 ET
MiNK Therapeutics | 10-Q: Q3 2024 Earnings Report
SECNov 14, 2024 16:14 ET · Announcements
MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript Summary
moomoo AINov 14, 2024 10:53 ET · Conference Call

Comments

Teddy123

Nov 7, 2024 09:15

MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

$MiNK Therapeutics (INKT.US)$
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced data from two poster pres...

Jaguar8

Nov 7, 2024 09:04

NEWS

$MiNK Therapeutics (INKT.US)$
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
MiNK Therapeutics presented new data at SITC 2024 showcasing their iNKT cell therapy programs. Their lead therapy agenT-797, alone or combined with anti-PD-1, demonstrated durable disease control in heavily pretreated patients. When combined with bispecific engagers targeting MUC16, HER2, Claudin 18.2, and DLL3, it showed enhanced T-cell activation and...

Jaguar8

Oct 4, 2024 10:41

NEWS

$MiNK Therapeutics (INKT.US)$
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
MiNK Therapeutics (NASDAQ: INKT) announced two poster presentations at the Society for Immunotherapy of Cancer's 29th Annual Meeting in Houston, Texas, from November 6-10, 2024. The presentations will showcase new preclinical data from MiNK's iNKT cell programs, agenT-797 and PRAME-TCR.
The first presentation, titled 'AgenT-797 cell therapy can be combined with next-generation immune checkpo...

Trytosaveabit

Jul 31, 2024 06:37

Update

$MiNK Therapeutics (INKT.US)$ Mink Therapeutics Regains Compliance With Nasdaq Capital Market Requirement

4

Trytosaveabit

May 22, 2024 06:36

Very cool for multiple reasons

$MiNK Therapeutics (INKT.US)$ NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced presentation of clinical data on agenT-797 in a complex case of severe acute respiratory distress (ARDS) at ...

INKT MiNK Therapeutics

Trade Overview

Capital Trend

News

Comments